JP2018083821A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018083821A5 JP2018083821A5 JP2017245743A JP2017245743A JP2018083821A5 JP 2018083821 A5 JP2018083821 A5 JP 2018083821A5 JP 2017245743 A JP2017245743 A JP 2017245743A JP 2017245743 A JP2017245743 A JP 2017245743A JP 2018083821 A5 JP2018083821 A5 JP 2018083821A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid position
- substitution
- wild type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/418,242 | 2012-03-12 | ||
| US13/418,242 US9175331B2 (en) | 2010-09-10 | 2012-03-12 | Inhibitors of human EZH2, and methods of use thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015500523A Division JP6321619B2 (ja) | 2012-03-12 | 2013-03-12 | ヒトｅｚｈ２の阻害剤およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018083821A JP2018083821A (ja) | 2018-05-31 |
| JP2018083821A5 true JP2018083821A5 (https=) | 2018-07-12 |
| JP6592071B2 JP6592071B2 (ja) | 2019-10-16 |
Family
ID=47913638
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015500523A Active JP6321619B2 (ja) | 2012-03-12 | 2013-03-12 | ヒトｅｚｈ２の阻害剤およびその使用方法 |
| JP2017245743A Active JP6592071B2 (ja) | 2012-03-12 | 2017-12-22 | ヒトｅｚｈ２の阻害剤およびその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015500523A Active JP6321619B2 (ja) | 2012-03-12 | 2013-03-12 | ヒトｅｚｈ２の阻害剤およびその使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| EP (2) | EP2825161B1 (https=) |
| JP (2) | JP6321619B2 (https=) |
| KR (4) | KR102267502B1 (https=) |
| CN (2) | CN104540500B (https=) |
| AU (4) | AU2013232229B2 (https=) |
| CA (2) | CA2867282C (https=) |
| DK (1) | DK2825161T3 (https=) |
| ES (1) | ES2718900T3 (https=) |
| HU (1) | HUE042271T2 (https=) |
| PL (1) | PL2825161T3 (https=) |
| PT (1) | PT2825161T (https=) |
| RU (2) | RU2704445C2 (https=) |
| TR (1) | TR201904660T4 (https=) |
| WO (1) | WO2013138361A1 (https=) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011160206A1 (en) | 2010-06-23 | 2011-12-29 | Morin Ryan D | Biomarkers for non-hodgkin lymphomas and uses thereof |
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| US9051269B2 (en) | 2011-11-18 | 2015-06-09 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| JP5989805B2 (ja) | 2012-02-10 | 2016-09-07 | コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | メチル基変更酵素の調節物質、組成物及びその使用 |
| US9394283B2 (en) | 2012-04-13 | 2016-07-19 | Epizyme, Inc. | Salt form of a human histone methyltransferase EZH2 inhibitor |
| SG10201608579UA (en) * | 2012-04-13 | 2016-12-29 | Epizyme Inc | Combination therapy for treating cancer |
| CA2884848C (en) * | 2012-09-28 | 2017-08-22 | Pfizer Inc. | Benzamide and heterobenzamide compounds |
| CA2887243C (en) | 2012-10-15 | 2024-04-09 | Epizyme, Inc. | Methods of treating cancer |
| PE20150887A1 (es) | 2012-10-15 | 2015-06-04 | Epizyme Inc | Compuestos de benceno sustituidos |
| US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| KR102142177B1 (ko) | 2013-10-16 | 2020-08-07 | 에피자임, 인코포레이티드 | Ezh2 억제용 하이드로클로라이드 염 형태 |
| EP3057594A4 (en) * | 2013-10-18 | 2017-06-07 | Epizyme, Inc. | Method of treating cancer |
| CA2931263A1 (en) | 2013-12-06 | 2015-06-11 | Epizyme, Inc. | Combination therapy for treating cancer |
| US20160361309A1 (en) * | 2014-02-26 | 2016-12-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treating cancer patients responding to ezh2 inhibitor gsk126 |
| IL285201B2 (en) * | 2014-06-17 | 2024-05-01 | Epizyme Inc | EZH2 inhibitors for the treatment of lymphoma |
| EP3158086B1 (en) | 2014-06-19 | 2021-03-24 | Memorial Sloan-Kettering Cancer Center | Biomarkers for response to ezh2 inhibitors |
| IL310279A (en) * | 2014-10-16 | 2024-03-01 | Epizyme Inc | Method for treating cancer |
| WO2016073956A1 (en) | 2014-11-06 | 2016-05-12 | Dana-Farber Cancer Institute, Inc. | Ezh2 inhibitors and uses thereof |
| HUE062159T2 (hu) * | 2014-11-17 | 2023-10-28 | Epizyme Inc | Módszer a rák kezelésére N-((4,6-dimetil-2-oxo-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H -pirán-4-il)amino)-4-metil-4'-(morfolinmetil)-[1,1'-bifenil]-3-karboxamiddal |
| UY36462A (es) | 2014-12-23 | 2016-07-29 | Novartis Ag | Compuestos de triazolopirimidina y usos de los mismos |
| WO2016172332A1 (en) * | 2015-04-22 | 2016-10-27 | The University Of North Carolina At Chapel Hill | A novel compound for the treatment of ewing sarcoma and high-throughput assays for identifying small molecules that modulate aberrant chromatin accessibility |
| EP3307713A4 (en) | 2015-06-10 | 2019-01-23 | Epizyme, Inc. | EZH2 INHIBITOR FOR THE TREATMENT OF LYMPHOMA |
| KR20180042356A (ko) | 2015-08-24 | 2018-04-25 | 에피자임, 인코포레이티드 | 암 치료 방법 |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
| JP7013369B2 (ja) * | 2015-09-25 | 2022-02-15 | エピザイム，インコーポレイティド | Ｅｚｈ２阻害剤により卵巣の悪性ラブドイド腫瘍（ｍｒｔｏ）／高カルシウム血症型の卵巣の小細胞癌（ｓｃｃｏｈｔ）を処置するための方法 |
| EP3371601A1 (en) | 2015-11-05 | 2018-09-12 | Epizyme Inc | Flow cytometry for monitoring histone h3 methylation status |
| JP7493304B2 (ja) * | 2016-04-22 | 2024-05-31 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｅｚｈ２インヒビターおよびそれらの使用 |
| WO2017201585A1 (en) * | 2016-05-26 | 2017-11-30 | Genea Ip Holdings Pty Ltd | Modulators of dux4 for regulation of muscle function |
| WO2017210395A1 (en) | 2016-06-01 | 2017-12-07 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
| EP3471830A4 (en) | 2016-06-17 | 2020-02-26 | Epizyme Inc | EZH2 INHIBITORS TO TREAT CANCER |
| EP3472166A1 (en) | 2016-06-20 | 2019-04-24 | Novartis AG | Imidazopyrimidine compounds useful for the treatment of cancer |
| ES2975263T3 (es) | 2016-06-20 | 2024-07-04 | Novartis Ag | Formas cristalinas de un compuesto triazolopirimidínico |
| WO2017221092A1 (en) | 2016-06-20 | 2017-12-28 | Novartis Ag | Triazolopyridine compounds and uses thereof |
| CN109843870A (zh) | 2016-10-19 | 2019-06-04 | 星座制药公司 | Ezh2抑制剂的合成 |
| AU2017351638A1 (en) | 2016-10-26 | 2019-06-13 | Genea Biocells USA (Holdings), Inc. | Improved generation of muscle lineage cells and therapeutic uses thereof |
| WO2018086592A1 (zh) * | 2016-11-11 | 2018-05-17 | 上海海雁医药科技有限公司 | 4,5,6-三取代吲唑类衍生物、其制法与医药上的用途 |
| CN106963765B (zh) * | 2017-03-28 | 2020-04-07 | 上海交通大学医学院附属第九人民医院 | Ezh2抑制剂化合物在制备治疗眼部黑色素瘤的药物中的应用 |
| US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| EP3630080A4 (en) | 2017-06-02 | 2021-03-10 | Epizyme, Inc. | USE OF EZH2 INHIBITORS TO TREAT CANCER |
| MX2020001875A (es) | 2017-08-18 | 2020-07-29 | Tragara Pharmaceuticals Inc | Forma polimorfica de tg02. |
| WO2019050924A1 (en) | 2017-09-05 | 2019-03-14 | Epizyme, Inc. | POLY THERAPY FOR THE TREATMENT OF CANCER |
| WO2019204998A1 (zh) * | 2018-04-25 | 2019-10-31 | 北京肿瘤医院 | Ezh2抑制剂在治疗粘膜型黑色素瘤中的应用 |
| WO2019233285A1 (en) * | 2018-06-03 | 2019-12-12 | Chen Wen Pin | Method for treating non-compaction cardiomyopathy |
| EP3831822A4 (en) * | 2018-07-27 | 2022-03-23 | Suzhou Sinovent Pharmaceuticals Co., Ltd. | POLY-SUBSTITUTED BENZENE COMPOUND, PROCESS OF MANUFACTURE AND USE THEREOF |
| EP3958854B1 (en) | 2019-04-22 | 2025-06-04 | University of Pittsburgh - of The Commonwealth System of Higher Education | Tg02 for use in treating gliomas in pediatric subjects |
| CN110960525A (zh) * | 2019-11-26 | 2020-04-07 | 济南大学 | 新型eed-ezh2相互作用抑制剂的确定和评价 |
| CN113024516B (zh) * | 2021-03-29 | 2022-05-17 | 中国药科大学 | 双靶点parp/ezh2抑制剂、制备方法及用途 |
| EP4392034A1 (en) | 2021-08-25 | 2024-07-03 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of ezh2 inhibitors for the treatment of aortic valve stenosis |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| CN119143880A (zh) * | 2024-09-20 | 2024-12-17 | 上海交通大学医学院附属第九人民医院 | 抗ezh2蛋白抗体及其应用 |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US7700293B2 (en) | 2001-08-02 | 2010-04-20 | The Regents Of The University Of Michigan | Expression profile of prostate cancer |
| EP1765994B1 (en) | 2004-06-01 | 2009-11-18 | The University of North Carolina at Chapel Hill | Reconstituted histone methyltransferase complex and methods of identifying modulators thereof |
| ES2324435B1 (es) * | 2005-10-27 | 2010-05-31 | Fundacion Para El Estudio De La Hematologia Y Hemoterapia De Aragon (Fehha) | Procedimiento y dispositivo de analisis in vitro de mrna de genes implicados en neoplasias hematologicas. |
| WO2008101118A2 (en) * | 2007-02-14 | 2008-08-21 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates |
| WO2009006577A2 (en) * | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| WO2009124137A2 (en) * | 2008-04-01 | 2009-10-08 | Mount Sinai School Of Medicine Of New York University | Method of suppressing gene transcription through histone lysine methylation |
| WO2012005805A1 (en) | 2010-05-07 | 2012-01-12 | Glaxosmithkline Llc | Azaindazoles |
| JP5864546B2 (ja) | 2010-05-07 | 2016-02-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | インダゾール |
| EA023788B1 (ru) | 2010-05-07 | 2016-07-29 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Производные индола и фармацевтические композиции на их основе |
| BR112013005806B1 (pt) * | 2010-09-10 | 2022-05-10 | Epizyme, Inc | Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2 |
| JO3363B1 (ar) * | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| CA2850570A1 (en) * | 2011-09-30 | 2013-04-04 | Glaxosmithkline Llc | Methods of treating cancer |
-
2013
- 2013-03-12 RU RU2014141045A patent/RU2704445C2/ru active
- 2013-03-12 KR KR1020147028560A patent/KR102267502B1/ko not_active Expired - Fee Related
- 2013-03-12 TR TR2019/04660T patent/TR201904660T4/tr unknown
- 2013-03-12 CN CN201380024734.7A patent/CN104540500B/zh active Active
- 2013-03-12 KR KR1020227034498A patent/KR102587175B1/ko active Active
- 2013-03-12 KR KR1020217018417A patent/KR102453519B1/ko active Active
- 2013-03-12 CA CA2867282A patent/CA2867282C/en active Active
- 2013-03-12 PL PL13711265T patent/PL2825161T3/pl unknown
- 2013-03-12 WO PCT/US2013/030565 patent/WO2013138361A1/en not_active Ceased
- 2013-03-12 CN CN201910052279.0A patent/CN110420327B/zh active Active
- 2013-03-12 EP EP13711265.2A patent/EP2825161B1/en active Active
- 2013-03-12 EP EP18214827.0A patent/EP3536314A1/en not_active Withdrawn
- 2013-03-12 KR KR1020237033924A patent/KR20230145531A/ko not_active Ceased
- 2013-03-12 JP JP2015500523A patent/JP6321619B2/ja active Active
- 2013-03-12 HU HUE13711265A patent/HUE042271T2/hu unknown
- 2013-03-12 RU RU2019132222A patent/RU2019132222A/ru unknown
- 2013-03-12 AU AU2013232229A patent/AU2013232229B2/en not_active Ceased
- 2013-03-12 ES ES13711265T patent/ES2718900T3/es active Active
- 2013-03-12 DK DK13711265.2T patent/DK2825161T3/en active
- 2013-03-12 PT PT13711265T patent/PT2825161T/pt unknown
- 2013-03-12 CA CA3177515A patent/CA3177515A1/en active Pending
-
2017
- 2017-12-22 JP JP2017245743A patent/JP6592071B2/ja active Active
-
2018
- 2018-02-19 AU AU2018201176A patent/AU2018201176A1/en not_active Abandoned
-
2019
- 2019-10-17 AU AU2019250181A patent/AU2019250181A1/en not_active Abandoned
-
2021
- 2021-04-07 AU AU2021202119A patent/AU2021202119A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018083821A5 (https=) | ||
| JP2015511603A5 (https=) | ||
| RU2014141045A (ru) | Ингибиторы ezh2 человека и способы их применения | |
| Van der Jeught et al. | Drug resistance and new therapies in colorectal cancer | |
| JP7504853B2 (ja) | 頭頸部扁上皮がんおよびその他のがんに対する免疫療法で使用するための新規ペプチドおよびスキャフォールド | |
| KR102284493B1 (ko) | 간세포 암종(hcc) 및 기타 암들에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합 | |
| JP2010519176A5 (https=) | ||
| IL258544A (en) | Combined treatment for cancer | |
| EP4226944A2 (en) | Tumor mutational load and checkpoint immunotherapy | |
| JP2018529698A5 (https=) | ||
| US20130195843A1 (en) | Biomarkers for Non-Hodgkin Lymphomas and Uses Thereof | |
| JP2016020389A5 (https=) | ||
| JP2016026215A5 (https=) | ||
| RU2018145311A (ru) | Способы лечения рака | |
| JP2013518055A5 (https=) | ||
| IL273254B1 (en) | HLA type II-restricted T cell receptors against RAS | |
| EA202090757A1 (ru) | T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53 | |
| JP2015525208A5 (https=) | ||
| JP2016532693A5 (https=) | ||
| JP2016508504A5 (https=) | ||
| RU2016124179A (ru) | СКОНСТРУИРОВАННЫЕ ВЫСОКОАФФИННЫЕ T-клеточные рецепторы человека | |
| SI3079715T1 (en) | A mixture of peptides | |
| FI3448879T3 (fi) | Claudin-6 -peptidejä | |
| EP4329780A1 (en) | T cell receptors directed against ras-derived recurrent neoantigens and methods of identifying same | |
| IL298653A (en) | New peptides and a combination of peptides for use in immunotherapy against several types of cancer |